Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Center for Common Disease Genomics [CCDG] - Cardiovascular: Pharmacokinetic Polymorphisms in Japanese General Population

ABSTRACT: Center for Common Disease Genomics [CCDG] - Cardiovascular: Pharmacokinetic Polymorphisms in Japanese General Population

PROVIDER: PRJNA856033 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Center for Common Disease Genomics [CCDG] - Cardiovascular: Pharmacokinetic Polymorphisms in Japanese General Population

Project description:Center for Common Disease Genomics [CCDG] - Cardiovascular: Pharmacokinetic Polymorphisms in Japanese General Population

| PRJNA856034 | ENA

Center for Common Disease Genomics [CCDG] - Cardiovascular: TAICHI

Project description:Center for Common Disease Genomics [CCDG] - Cardiovascular: TAICHI

| PRJNA419022 | ENA

Center for Common Disease Genomics [CCDG] - Cardiovascular: TexGen

Project description:Center for Common Disease Genomics [CCDG] - Cardiovascular: TexGen

| PRJNA865439 | ENA

Center for Common Disease Genomics [CCDG] - Cardiovascular: TexGen

Project description:Center for Common Disease Genomics [CCDG] - Cardiovascular: TexGen

| PRJNA865440 | ENA

Center for Common Disease Genomics [CCDG] - Cardiovascular: TAICHI

Project description:Center for Common Disease Genomics [CCDG] - Cardiovascular: TAICHI

| PRJNA419021 | ENA

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): Massachusetts General Hospital Atrial Fibrillation (MGH AF) Study

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): Massachusetts General Hospital Atrial Fibrillation (MGH AF) Study

| PRJNA309734 | ENA

Serum Predose Metabolic Profiling For Prediction Of Rosuvastatin Pharmacokinetic Parameters In Healthy Volunteers

Project description:Rosuvastatin is a quite known lipid-lowering agent generally used for hypercholesterolemia treatment and coronary artery diseases prevention. There is substantial inter-individual variability in the absorption of statins usually caused by genetic polymorphisms leading to variation in the corresponding pharmacokinetic parameters, which may affect drug therapy safety and efficacy. Therefore, the investigation of metabolic markers associated with rosuvastatin inter-individual variability is exceedingly relevant for drug therapy optimization and minimizing side effects. This work describes the application of pharmacometabolomics strategies using liquid chromatography coupled to mass spectrometry to investigate endogenous plasma metabolites capable of predicting pharmacokinetic parameters in predose samples. First, a targeted method for the determination of plasma concentration levels of rosuvastatin was validated and applied to obtain the pharmacokinetic parameters from the 40 enrolled individuals, then predose samples were analyzed using the metabolomics approach to search for associations between endogenous metabolites and the corresponding pharmacokinetic parameters. Data processing using machine learning revealed some candidates including sterols and bile acids, carboxylated metabolites as well as lipids suggesting the approach herein described as promising for personalized drug therapy.

2021-10-29 | MTBLS3128 | MetaboLights

Center for Common Disease Genomics (CCDG) - Cardiovascular: Emory Cohort

Project description:Center for Common Disease Genomics (CCDG) - Cardiovascular: Emory Cohort

| PRJNA559940 | ENA

Center for Common Disease Genomics (CCDG) - Cardiovascular: Emory Cohort

Project description:Center for Common Disease Genomics (CCDG) - Cardiovascular: Emory Cohort

| PRJNA559941 | ENA

Center for Common Disease Genomics (CCDG) - Cardiovascular: BioImage Cohort

Project description:Center for Common Disease Genomics (CCDG) - Cardiovascular: BioImage Cohort

| PRJNA690606 | ENA